The responsiveness and validity of the CAMPHOR Utility Index
Authors:
- D. M. MeadsDMD. M. Meads
- N. DoughtyNDN. Doughty
- J. Pepke-ZabaJPJ. Pepke-Zaba
Open Access
- 3 September 2008
- journal article
- research article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 32 (6) , 1513-1519
Abstract
The aim of the present study was to validate and determine the mininal important difference (MID) and responsiveness of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) Utility Index, a new tool enabling cost utility analyses.CAMPHOR, 6-min walking test (6MWT) and New York Heart Association (NYHA) data for 869 pulmonary hypertension patients (545 (63%) female; mean±sdage 56.6±15.4 yrs) from three centres were analysed. Utility was correlated with 6MWT data and calculated by NYHA class to assess validity. Effect sizes were calculated for those with two CAMPHOR assessments. Distribution and anchor-based MIDs were calculated. Analyses were carried out in patients receiving bosentan in order to determine whether or not those remaining in NYHA class III following treatment improved.The Utility Index distinguished between adjacent NYHA classes and correlated with 6MWT results. CAMPHOR subscales and utility were as responsive as the 6MWT (effect sizes ranged 0.31–0.69 for the CAMPHOR and 0.16–0.34 for the 6MWT). The within-group MID for the Utility Index was estimated to be ∼0.09. Patients remaining in NYHA class III experienced, on average, a significant improvement (CAMPHOR Utility Index and functioning), which exceeded the MID.The CAMPHOR Utility Index is valid and responsive to change. Patients can experience significant and important improvements even if they do not improve on the basis of traditional outcomes, such as NYHA functional class.Keywords
This publication has 30 references indexed in Scilit:
- Pulmonary Arterial HypertensionJACC, 2008
- Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomesJournal of Clinical Epidemiology, 2008
- Quality of Life in Pulmonary Arterial Hypertension: Improvement and Maintenance With BosentanThe Journal of Heart and Lung Transplantation, 2007
- The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary HypertensionQuality of Life Research, 2006
- Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.2004
- An integrated method to determine meaningful changes in health-related quality of lifeJournal of Clinical Epidemiology, 2004
- The estimation of a preference-based measure of health from the SF-36Journal of Health Economics, 2002
- Quality of life questionnaires: Does statistically significant = clinically important?Journal of Allergy and Clinical Immunology, 1998
- Comparison of Quality of Well-Being scale and NYHA functional status classification in patients with atrial fibrillationAmerican Heart Journal, 1998
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990